Nano-Strategies for Improving the Bioavailability of Inhaled Pharmaceutical Formulations

Author(s): Yue Xing, Peng Lu, Zhifeng Xue, Chunxia Liang, Bing Zhang, Dereje Kebebe, Hongfei Liu, Zhidong Liu*.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 20 , Issue 13 , 2020

Become EABM
Become Reviewer


Pulmonary pharmaceutical formulations are targeted for the treatment of respiratory diseases. However, their application is limited due to the physiological characteristics of the lungs, such as branching structure, mucociliary and macrophages, as well as certain properties of the drugs like particle size and solubility. Nano-formulations can ameliorate particle sizes and improve drug solubility to enhance bioavailability in the lungs. The nano-formulations for lungs reviewed in this article can be classified into nanocarriers, no-carrier-added nanosuspensions and polymer-drug conjugates. Compared with conventional inhalation preparations, these novel pulmonary pharmaceutical formulations have their own advantages, such as increasing drug solubility for better absorption and less inflammatory reaction caused by the aggregation of insoluble drugs; prolonging pulmonary retention time and reducing drug clearance; improving the patient compliance by avoiding multiple repeated administrations. This review will provide the reader with some background information for pulmonary drug delivery and give an overview of the existing literature about nano-formulations for pulmonary application to explore nano-strategies for improving the bioavailability of pulmonary pharmaceutical formulations.

Keywords: Nano-strategies, pulmonary pharmaceutical formulations, bioavailability, nanocarriers, no-carrier-added nanosuspensions, polymer-drug conjugates.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [1258 - 1271]
Pages: 14
DOI: 10.2174/1389557520666200509235945
Price: $95

Article Metrics

PDF: 3